Karkinos Healthcare, a technology-driven cancer care platform in India, has entered a strategic partnership with American oncology diagnostics firm C2i Genomics to promote AI-enabled cancer monitoring in the country. their partnership will expand minimal residual disease (MRD) monitoring across Karkinos’ network using C2i Genomics’ whole-genome analysis platform. MRD refers to the small number of cancer cells remaining in a patient’s body after treatment. Karkinos operates a distributed cancer care network model, coordinating healthcare institutions and professionals to deliver streamlined access to cancer care. It is currently present in some locations across eight Indian states and in India’s National Capital Region.
Karkinos adds to the growing list of C2i Genomics’ partners who adopted its MRD monitoring platform, including Singaporean biotech company NovogeneAIT Genomics and NuProbe, a genomics company that also operates in China. Karkinos Healthcare shares in our vision to increase access to distributed cancer monitoring and will be instrumental in advancing our commercialization efforts to bring the C2inform MRD test to labs across India.